timothy sykes logo

Stock News

ImmunityBio’s Stock on Vanguard: What Lies Ahead?

Bryce TuoheyAvatar
Written by Bryce Tuohey Reviewed by Matt Monaco Fact-checked by Bryce Tuohey
Updated 9/15/2025, 5:04 pm ET 9/15/2025, 5:04 pm ET | 6 min 6 min read
ImmunityBio’s Stock on Vanguard: What Lies Ahead? Thumbnail

ImmunityBio Inc. stocks have been trading up by 5.77 percent following favorable developments in their leading pipeline therapies.

  • New Phase 2 trials for Anktiva target long COVID, aiming to enhance NK cell responses with IL-15 agonist properties, showcasing a strategic pivot for ImmunityBio beyond oncology into broader public health concerns.

  • The pilot study targeting glioblastoma delivers promising disease control across all patients, signaling potential new frontiers for ImmunityBio’s therapeutic proteins.

  • An innovative platform, the BioShield, anchored by Anktiva, embarks on a Phase 2 exploration for long COVID, highlighting ImmunityBio’s adaptation and growth potential in varied medical issues.

  • Healthcare discussions regarding cutting-edge treatment for bladder cancer feature ImmunityBio’s involvement, underscoring its expanded footprint in diversified cancer therapy landscapes.

Candlestick Chart

Live Update At 17:04:17 EST: On Monday, September 15, 2025 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 5.77%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of ImmunityBio’s Financial Health:

When aspiring traders set out on their journey, they often focus solely on the potential profits that can be made. However, successful trading involves much more than just raking in money. As millionaire penny stock trader and teacher Tim Sykes says, “It’s not about how much money you make; it’s about how much money you keep.” This principle underlines the importance of strategic planning, effective risk management, and disciplined decision-making in preserving and growing one’s trading capital over time. Understanding this critical distinction is often what separates those who thrive in the trading world from those who merely dabble in it.

ImmunityBio, represented by IBRX, has sparked interest due to its latest market moves and scientific breakthroughs. With $15.4M in revenue, its price-to-sales stands astoundingly high at 78.72, reflecting an ambitious vision backed by hefty enterprise value. Despite the stark negative EBIT margin of -476.5%, the company exhibits a current ratio of 4.1, demonstrating a stable ability to meet short-term liabilities.

Market reactions tend to follow ImmunityBio’s clinical announcements closely. Recent data indicate significant upward movement in share price, specifically on Sep 15, 2025, with a closing value at $2.74, advancing from the previous $2.57 on Sep 9. This aligns with the company’s impressive Phase 2 Anktiva results, where effective lymphopenia reversal has attracted widespread acclaim and potential investor interest.

However, a broader look shows the company wrestling with some challenges; notably, the asset turnover is at a low of 0.1, suggesting underutilization of assets in generating revenue. Equally significant is the ballooning negative return on assets at -114.61, emphasizing profitability hurdles despite operational expansion.

ImmunityBio’s financials echo its innovation-driven yet high-risk strategy. With ongoing R&D, particularly in the cancer and long COVID arenas, the company seems poised to redefine traditional revenue channels, banking on robust clinical success.

Clinical Breakthroughs Fuel Stock Momentum

The market has turned its keen eye towards ImmunityBio as its experimental drug Anktiva shows transformative results in clinical trials. Patients suffering from advanced lung cancer have seen extended survival rates, a testament to Anktiva’s efficacy in reversing treatment-resilient lymphopenia. Moreover, the goal to treat long COVID through new trials nurtures hopes for addressing a pervasive and elusive post-pandemic issue.

Investors, spurred by these promising clinical insights, have driven demand for IBRX stock. Yet, caution tempers enthusiasm as the broader market digests stratospheric future cash flow predictions against present financial strain. The dual-edged sword of innovation coupled with static revenue streams hath not been lost on analysts.

Nonetheless, the manifold applications of ImmunityBio’s pipeline support the thesis for sustained, albeit tempered, growth. The scientific success of Anktiva in glioblastoma trials also fuels optimism. As the healthcare sector eagerly watches, ImmunityBio taps into diversified indications, potentially heralding lucrative outcomes if trials succeed in broader patient bases.

More Breaking News

Financial Data Raises Questions Over Market Valuation

Hypothetical musings aside, the concrete numbers of ImmunityBio’s financial reports articulate a complex tapestry. Capital expenditure remains negative, spotlighting ongoing investments in clinical gears and expansions. Meanwhile, the eponymous Anktiva has contributed to diluting operational earnings, leading to net losses.

Traders seeking profits must square these outputs with ImmunityBio’s forecast of long-term opportunity. Rising numbers of common shares outstanding (945M) and a negative retained earnings figure underline the high stakes at play. By utilizing proceeds towards research frontiers, the company stakes its future on groundbreaking drug success.

In summation, ImmunityBio’s financial narrative is disparate, ultra-innovative, yet hobbled by operational difficulties typical of biopharma startups. Its stock seduces through storytelling amid experimental evidence, suggesting potential industry disruption. As J.D. Rockefeller once said, the best time to buy is when there is blood on the streets, implying for ImmunityBio an opportune moment to align stakes with scientific anticipation. Will forthcoming trials fortify this fate, or will they amplify the fiscal woes? As millionaire penny stock trader and teacher Tim Sykes says, “There is always another play around the corner; don’t chase just because you feel FOMO.” Traders and analysts alike are on edge, awaiting the unfolding story.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Bryce Tuohey

Mentor and Trainer at StocksToTrade.com, Lead Mentor at Small Cap Rockets and To The Moon Report
Bryce’s first pattern was buying into strength in breakouts. But he noticed when they didn’t work, he took bigger losses. When the OTC market got hot, Bryce learned to dip buy the inevitable panics. He adapted his breakout strategy and now buys consolidation and trend breaks. His goal is to have better risk/reward and get an entry before multi-day listed breakouts.
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”